Dtsch Med Wochenschr 2011; 136(17): 897
DOI: 10.1055/s-0031-1275825
Pro & contra | Commentary
Onkologie, Chirurgie
© Georg Thieme Verlag KG Stuttgart · New York

Metastasenchirurgie bei neuroendokrinen Tumoren – contra

Resection of metastases in neuroendocrine tumors: contraU. -F. Pape1
  • 1Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin
Further Information

Publication History

Publication Date:
26 April 2011 (online)

Literatur

  • 1 Ahmed A, Turner G, King B. et al . Midgut neuroendocrine tumours with liver metastases. Results of the UKI NETS study.  Endocr Relat Cancer. 2009;  16 885-894
  • 2 Cho C S, Labow D M, Tang L. et al . Histologic Grade Is Correlated With Outcome After Resection of Hepatic Neuroendocrine Neoplasms.  Cancer. 2008;  113 126-1134
  • 3 Pape U F, Berndt U, Müller-Nordhorn J. et al . Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.  Endocr Relat Cancer. 2008;  15 1083-1097
  • 4 Scigliano S, Lebtahi R, Maire F. et al . Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15 year monocentric experience.  ENdocr Relat Cancer. 2009;  16 977-990
  • 5 Strosberg J R, Fine R L, Choi J. et al . First-Line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.  Cancer. 2011;  117 268-275

Dr. med. U.-F. Pape

Med. Klinik m. S. Hepatologie und Gastroenterologie
Charité – Universitätsmedizin Berlin
Campus Virchow Klinikum

Augustenburger Platz 1

13353 Berlin

Email: ulrich-frank.pape@charite.de